ALTABAX is indicated for the treatment of impetigo due to Staphylococcus aureus* and Streptococcus pyogenes in adults and children as young as 9 months old. With the tolerability, convenience and the ease-of-use of a topical, FDA-approved ALTABAX effectively treats impetigo with simple 5-day b.i.d. dosing.
References:
- Kosowska-Shick K, Clark K, Credito K, et al. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother. 2006;50:765-769.
Important Safety Information
*ALTABAX is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.
The most common drug-related adverse reaction was application site irritation (1.4% of patients).
Please see complete Prescribing Information for ALTABAX
This site is intended for US healthcare professionals only.
© 1997-2008 GlaxoSmithKline. All Rights Reserved.
